

August 16, 2018

To,

BSE Ltd., Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai - 400 001

Ref.: BSE Scrip Code - 539730

Subject: Newspaper Advertisement of the Financial Statements for Quarter ended June 2018

Dear Sir / Madam,

In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for Quarter ended June 2018; as approved by the Board in its Meeting held on Tuesday, August 14, 2018; published in Navshakti and Free-press Journal on August 15, 2018.

Kindly take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited Fredun Medhora Managing Director

Encl. - A/a

	DECORCO Econecycling Limited Regd. office Near Cline M	ECYCLING MH1994PLC079971 2 422, 4 th Floor, The S ax Theatre, Andheri anak Pump, Andheri (The Quarter Ent	Summit Busines Kurla Road, E), Mumbai - 40 Terti 3 011h Jun	0 093. 1e, 2018
Sr.		Unuar		n thousands Audited
эг. 10.		Contraction and the state of th	Quarter ended 30.06.2017	Sector Contraction of the Contraction of the
	Total Income from Operations	13,642	46,037	141,722
	Net Profit/(Loss) for the period/year before tax and exceptional items Net Profit/(Loss) for the period/year before tax	(4,487)	5,585	5,696
	but after extraordinary items Net Profit/(Loss) for the period/year after tax and	(4,487)	5,585	(84,399)
	extraordinary items	(4,487)	5,585	(84,399)
	Total Comprehensive Income for the period/year	(8,347)	4,643	(38,474)
3	Pald-up Equity Share Capital Reserves (excluding revaluation reserve)	175,425	175,425	175,425
3	Basic for discontinued & continuing operations	(0.26)	0.32	(4.81)
	Diluted for discontinued & continuing operations	(0.26)	0.32	(4,81)

Visible annes houres in

For and on Behalf of The Board of Directors

the BSE (www.bseindla.com

invare listed



신티크전여리고 篇 阿·【:【》】:《·】【》】 CIN: L74239MH1982PLC026341 Regd. Office: 18, Shreeji Bhuvan, 51, Mangaidas Road, Princess Street, Mumbai - 40 Tel.: 022-66372841 Fax.: 022-22015441

Unaudited Standalone Results for the Quarter Ended Ju

Sr.	Particulars	Standalons Three Months Ended					
No.							
			Quarter ended March 31, 2018				
		Unaudited	Audited	Audi			
1	Total Income from Operations	1309.55	1299.65	107			
2	Net Profit / (Loss) for the period before Tax and Exceptional items	115.98	39.43	(13			
3	Net Profit / (Loss) for the period after tax	81.27	. 38.46	(13			
4	Total Comprehensive Income for the period(after tax)	81.27	38.46	(13			
5	Equity Share Capital	120.00	120.00	1.			
6	Earnings Per Share (of Rs. 10/- each) * 1. Basic 2. Dilutad	6.77 6.77	3.21 3.21	(1 (1			

- The above results have been reviewed by the Audit Committee and approved by the Board of held on August 14, 2018. The financial results of the Company have been prepared in accordance with Indian Account notified under Section 133 of the Companies Act, 2013 read with the relevant rules of Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting 3 Rules, 2016.
- Nules, 2016. The business of the Company fall under Single Segment i.e. "Pharmaceuticals Products." The above is an extract of the detailed format of Quarterly Financial Results filed with the Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 201 Quarterly/Annual Financial Results are available on the Stock Exchange websites.
 - www.mercurylabs.com For

Place: Vadodara

अ. क.

1

₹.

٩.

nŝ.

Date: 14th August, 2018

FREDUN PHARMACEUTICALS LTD. CIN: L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G. D. Ambekar Marg, Wadala, Mumbai - 400 031 Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133 Email: business@fredungroup.com Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

			•	(Rs. In Lac
Sr. No.		Quarter	Year Ended	
	Particulars	June 2018 (Unaudited)	June 2017 (Unaudited)	March 2018 (Audited)
2012	Total Income from Operations	1651,73	930.27	5971.08
	Net Profit / (Loss) for the period			
	(before Tax, Exceptional and / or Extraordinary items#)	135.60	45.03	264.17
	Net Profit / (Loss) for the period before tax		н	
	(after Exceptional and / or Extraordinary items#)	(62.94)	45.03	264.1
	Net Profit / (Loss) for the period after tax		840.0	
	(after Exceptional and / or Extraordinary items#)	(62.94)	37.03	175.0
N. 9	Total Comprehensive Income for the period			
	[Comprising Profit / (Loss) for the period (after tax)			
	and Other Comprehensive Income (after tax)]	(62.94)	37.03	175.0
	Equity Share Capital	344.72	237.45	344.7:
306	Reserves (excluding Revaluation Reserve) as shown in			
	the Audited Balance Sheet of the previous year	•	-	1871.5
	Earnings Per Share (of Rs. 10/- each)			
	(for continuing and discontinued operations) -		4 50	r o
	1. Basic : A second secon	00	1,56	5.0
8 1 2	2. Diuted :	1 00	1.56	5,0

Note:

a) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com The amount of INR 198.54 Lakhs shown as provision for doubtful debts under pt. no. 4(g) of the Financia

Results from M/s. Moonlink Pharmaceuticals Limited of Uganda. The management has applied to ECGC for recovery and is quite confident of recovering the amount. However, following the principles of prudence the Company has provided for the full amount recoverable from M/s. Moonlink Pharmaceuticals Limited of Uganda.

For Fredun Pharmaceuticals Limited Sdl Fredun Medhora

Managing Director & Compliance Officer

Place : Mumbai Date : August 14, 2018 ठिकाण : मुंबई दिनांक : १५.०८.२०१८

३०.०६.२०१८ रोती संपलली रिमाही/ तप्रशील ३१.०३.२ संपलेल गरीरक व विद्यमान वर्ष परिवालनातून एकूण उत्पन्न (निव्वळ) 4027.54 कालावधीकरिता निव्वळ नफा/ (तोटा) (कर, अपवादात्मक य/वा अतिविशेष **₹**¥.९0 वाबींपूर्व) करपूर्व कालावधीकरिता निष्वळ नफा/ (तोटा) (अपवादात्मक व/वा अतिविशेष **१४.९**० बाबीपरचात) करपश्चात कालावधीकरिता निव्वळ नेफा/ (तोटा) (अपवादात्मक व/वा **११.**०३ अतिविशेष बाबीपश्चात) कालावधीकरिता एकण सर्वसमाधेशक उत्पन्न (कालावधीकरिता (करपश्चात) 88.03

	नफा/(तोटा) व अन्य सर्वसमावेशक ठत्पन्न (करपञ्चात) याचा समावेश)		
Ŀ,	समधान पांडवल	₹३९४.९७	
6.	राखीव (गत वर्षाच्या लेखापरीक्षित ताळेवदामध्ये दर्शविस्यानुसार पुनर्युल्यांकन राखीव वगळता)	-	
۵.	उत्पन प्रतिशेञ् (दर्शनी मूल्य प्रत्येकी रु. १०/-) (चालू व अखंडित परिचालगकरिता) (अवार्षिकीकृत)		
	मूलामूह	0.06	
×.	सौम्पीकृत	0.02	

वरील निर्देशित विवरण हे सेनी (सूची व अन्य विमोचन आवश्यकता) विनियमन, २०१५ च्या विनियमन ३३ अं न्तराः नगराः मन्त्र करणात आतंत्यां तिपादी निर्वाव निष्कर्षांच्या विस्तृत प्रारूपाचा सार्यत्र आहे. तिमाही न वर्षअखेरीच्या वितीय एतसचेबेसची वेबसाइट अर्थात बीएसई लिभिटेह व एमएसई लिभिटेहकडे अनुक्रमें <u>www.bseincia.com</u> व wo वेस्साइट <u>www.abarisenterpries.com</u> बाही उपलम्प आहे. वरीत विष्कृषीचे लेखापरीक्षण सनितीद्वारे पुरायवलोकन करण्यात आले. असून कंपनीच्या संचालक पंढळाद्वारे ल्यांप

पडलेल्या सभेत त्यांना मंजुरी देण्यात आली आहे.

भडलपथ बनाइ स्पना नयुरा प्रभाग आदा. आत्म काल्य आत्म स्वर्ग्यात्र प्रतित्व वार्या संस्थान नियम तसेच भारतात सं सर्वात निष्कृति संस्थान संस्थत, १०१३ चे अनुच्खेद १३३ सहमाचन त्याजतात जारी मंतरम नियम तसेच भारतात सं प्रोरणतातीत मारतीय लेखा मानकातुसार (आवश्तडी प्रएस) तयार करण्यात आतेले आहेत. त्यानुसार, गत कालावधीकरिय पुनःवर्षीकृत/पुनर्गठित/पुनःनम्द् आहे

अबन्स

अबन्स एन्टरप्रायझेस लिमिटेर

मोंदणीकृत कार्यालय : ३६/३७/३८५, ३ रा मजला, २२७, नरियन भवन, बॅकवे रेक्लेमेशन, नरियन पॉइंट,

दूर. क. ०२२-६१७९०००० ई-मेल : compliance@abansenterprises.com वेबसाइट : www.ab

सीआवएन : L74120MH1985PLC035243

दि. ३० जून, २०१८ रोजी संपलेल्या तिमाहीकरिताच्या अलेखापरीक्षि

वित्तीय निष्कर्षांच्या अहवालाचा सारांश

THE FREEPRESS JOURNAL awwwitteepnessioutnallin MUMBALI WEDNESDAY | AUGUST 15, 2018

-	Kridhan Infra Limited Regd. Office: A/13, Cross Road No. 5, Kondivita Road, MIDC, Marol, Andheri (East), Mumbei: 400 093 CIN: 1271000H2006PLC160602 * Tei U22 40569569 * Web; www.kridhan.com * Email: cs@kridhan.com								
	STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018								
			Standalor	10		Consolidate	₹ <u>in Lacs</u> ad		
Sc.		Quarte	rended	Year ended	Quarte	er ended	Year ended		
	Particulars	30-05-2018	30-06-2017	31-03-2018	30-05-2018	30-06-2017	31-03-2018		
1	no este la la regiona de la deserver	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited		
ſ	Total Income from Operations	823	2,529	8,801	19,289	18,531	71,248		
2 9	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items) Net Profit / (Loss) for the period before tax (after	404	23	. 779	1,601	1,231	6,023		
4	Exceptional and/or Extraordinary items) including profit from associate Net Profit / (Loss) for the period after tax (after	29	23	129	1,597	1,197	4,429		
r u	Exceptional and/or Extraordinary items) including profit from associate Total Comprehensive income for the period	22	12	82	1,449	1,072	3,950		
	[Comprising Profit / (Loss) for the period (after (ax) and Other Comprehensive Income (after tax)] including profit from associate	22	12	82	1,449	1,072	3,950		
6	Equity Share Capital	1,896	1,482	1,896	1,896	1,482	1,896		
7	Reserves (excluding Reveilation Reserve) as shown in the Audited Balance Shaet of the previous year Earnings Per Share (of Rs. 2/- each) (for	- -		-8,139	-		27,750		
	continuing and discontinued operations) 1. Basic: 2. Diluted:	0.02 0.02	-0.02 0.02	0.10 0.10	1.45 1.42	1.42 1.42	4.74 4,69		
13 m	Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stack Exchanges under Regulation 31 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange website www.bseindia.com & www.nseindia.com, and our Company's website www.bhan.com. For and on behalf of the Board of Directors Kridhan Infra Limited Sdi- Place : Mumbai Date : 14/08/2018								

VINADITYA TRADING COMPANY LIMITED

CIN - L51900MH1981PLC024340

Regd. Office: Office No: 12, 4" Floor, 68, Sal Sadan, Janmabhoomi Marg, Hutatma Chowk, Fort, Mumbai 400001, Maharashtra E-mail: info@aacs.in Web: www.vinaditya.com Extract of Standalone Financial results for the guarter ended on 30th June 2018. (Rs. In Lacs

	and the second	ins. in causi		
Particulars	Quarter ended on 30.06.2018	Quarter ended on 31.03.2018	Quarter ended on 30.06.2017	Financial year ended on 30,03.2018
	Unaudited	Audited	Audited	Audited
Total revenue from operations		3.02		3.02
Net Profit / (Loss) for the period (before tax and exceptional items)	(10.32)	6.04	(2.34)	1.99
Net Profit / (Loss) for the period before tax (after exceptional items)	, (10.32)	6.04	(2:34)	1.99
Net Profit/(Loss)for the period after tax	(10.32)	5.49	(2.34)	1.44
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax) Paid up Equity Share Capital [Face	(10.32)	5.49	(2.34)	1.44
value of Rs 10 per share]	720.00	720.00	720.00	720.00
Basic earning per share of Rs.10 each (not annualized) in rupees (after exceptional items)	(0.14)	0.08	(0.03)	0.02
Diluted earning per share of Rs 10 each (not annualized)- in rupees (after exceptional items)	(0.14)	0.08	(0.03)	0.02

Notes

Access: a) The above is an extract of the detailed format of standalone results for the quarter ended on 30th June 2018 approved at the Board meeting held on August 13, 2018 and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulation, 2015. The full format of the Standalone results for the quarter ended on 30th June, 2018 are available on the websites of the Stock Exchanges (www.nseindia.com/www.bseindia.com) and the Company's website (www.vinaditya.com).

For VINADITYA TRADING COMPANY LIMITED

Sd/-

Satyaprakash Satyanarayan Pathak

DIN:- 00884844

Wholetime Director Dated : 13.08.2018 Mumbai

ABANS ENTERPRISES LIMITED CIN: L74120MH1985PLC035243

Regd. Office: 36,37,38A, 3rd Floor, 227, Nariman Bhavan, Backbey Reclamation, Nariman Point, Mumbei-400021. Tel No.: 022-61790000, Email: compliance@abansenterprises.com. Web: www.abansenterprises.com

Extract of Statement of Un-Audited Financial Results for quarter ended June 30, 2018

	(Rs. in lakins Except E					
Sr. No.	Particulars	Quarter ending / Current Year Ending - 30.05.2018	Year to date Figures / Previous Year Ending 31.03.2018	Corresponding 3 months ended in the previous year- 30.062017		
t.	Total income from operations (net)	5082.65	6972.37	640.64		
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	14.90	23.66	9,18		
ą	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	14.90	23.66	9.18		
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	11.03	17.40	6.34		
5	Total Comprehensive income for the period [Comprising profit/ (loss) for the period (after tax) and other Comprehensive Income (after tax)]	11.08	17.40	6.34		
6	Equity Share Capital	1394.97	1394.97	1394.97,		
7.	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet)		84.98			
8.	Earnings Per Share (Face value of Rs. 10/- each) (for continuing and discontinuing operations) (not annualised)					
	Basic:	0.08	0.12	0.05		
	Diluted:	0.08	0.12	0.05		

Notes

The above is an extract of the detailed format of quarterly financial results for the period filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full detailed quarter & year ended financial results are available on the stock exchanges website i.e. BSE Limited and MSEI Limited www.bseindla.com & www.msei.com respectively and also on company's website the stock exchanges. www.abansenterprises.com.

The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in its meeting held on 14th August, 2018.

The above results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Accordingly, previous period's figures have been reclassified/regrouped/ restated, wherever necessary.

By Order of the Board For ABans Enterprises Limited

Place: Mumbal

Sd/

Abhishek Bansa **Managing Director**

Date: 15th August, 2018

FREDUN PHARMACEUTICALS LTD.

CIN: L24239MH1987PLC043662 Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031 Phone Number: +91 22 4031 8111 Fax. +91 22 4031 8133 Email: business@ifredungroup.com Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

		Quarter	Year Ended	
Sr, No.	Particulars	June 2018 (Unaudited)	June 2017 (Unaudited)	March 2018 (Audited)
1. 2	Total Income from Operations Net Profit / (Loss) for the period	1651.73	930.27	5971.08
3.	(before Tax, Exceptional and / or Extraordinary items#)	135.60	45.03	264.17
4.	(after Exceptional and / or Extraordinary items#)	(62.94)	45.03	264.17
	(after Exceptional and / or Extraordinary items#) Total Comprehensive Income for the period	(62.94)	37.03	175.09
	[Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(62.94)	37.03	175.09
6. 7.	Equity Share Capital Reserves (excluding Revaluation Reserve) as shown in	344.72	237.45	344.72
8.	the Audited Balance Sheet of the previous year Earnings Per Share (of Rs. 10/- each)	•		1871.54
	(for continuing and discontinued operations) - 1. Basic :	00	1.56	5.07
	2. Diluted :	00	1.56	5.07

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com a) and of the Company at www.fredungroup.com

The amount of INR 198.54 Lakhs shown as provision for doubtful debts under pt. no. 4(g) of the Financial Results from M/s. Moonlink Pharmaceuticals Limited of Uganda. The management has applied to ECGC for b) recovery and is quite confident of recovering the amount. However, following the principles of prudence the Company has provided for the full amount recoverable from M/s. Moonlink Pharmaceuticals Limited of Uganda.

10 2 65

Line Line and March

For Fredun Pharmaceuticals Limited

Place : Mumbai Date : August 14, 2018

Note

Fredun Mødhora Managing Director & Compliance Officer



HIGH GROUND ENTERPRISE LIMITED

PUBLIC NOTICE

I Mr. Sadanand Mahadev Revendekar declare that my ownership Flat in 12/A/13 Meenskipi Nagari Niyara